SS
ALNY icon

Steve Schonfeld’s Alnylam Pharmaceuticals ALNY Stock Holding History

Steve Schonfeld’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-30,000
Closed -$7.29M – 2011
2024
Q2 		$7.29M Sell
30,000
-24,000
-44% -$3.79M 0.05% 446
2024
Q1 		$8.07M Buy
+54,000
New +$9.01M 0.05% 459

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steve Schonfeld's ALNY Position: Q2 2026 in Review

Steve Schonfeld reduced its Alnylam Pharmaceuticals (ALNY) stake by 57% in Q2 2026, selling an estimated $12.3M and leaving 31,112 shares worth $9.37M. The position accounts for 0.03% of the portfolio, ranked #434.

Steve Schonfeld first reported a position in ALNY in Q3 2016 and has held it in 26 quarters since. The position peaked at $35.2M in Q1 2024. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Steve Schonfeld held 31,112 shares of Alnylam Pharmaceuticals worth $9.37M as of Q2 2026.
  • Steve Schonfeld sold 40,655 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $12.3M.
  • Alnylam Pharmaceuticals made up 0.03% of Steve Schonfeld's portfolio in Q2 2026, its #434 holding.
  • Steve Schonfeld first reported a position in Alnylam Pharmaceuticals in Q3 2016 and has held it in 26 quarters since.
  • Steve Schonfeld's Alnylam Pharmaceuticals position peaked at $35.2M in Q1 2024.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.